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Abstract 
Background  
Both acute myocardial ischemia and reperfusion contribute to cardiomyocyte death in ST-
elevation myocardial infarction (STEMI). The final infarct size is the principal determinant of the 
subsequent clinical outcome in STEMI patients. In a proof-of-concept phase II trial, the 
administration of cyclosporine prior to primary percutaneous coronary intervention (PPCI) has 
been associated with a reduction of infarct size in STEMI patients.  
Methods 
CIRCUS is an international, prospective, multicenter, randomized, double-blinded, placebo-
controlled trial. The study is designed to compare the efficacy and safety of cyclosporine versus 
placebo, in addition to revascularization by PPCI, in patients presenting with acute anterior 
myocardial infarction within 12 hours of symptoms onset and initial TIMI flow≤1 in the culprit 
left anterior descending coronary artery. Patients are randomized in a 1:1 fashion to 2.5mg/kg 
intravenous infusion of cyclosporine or matching placebo performed in the minutes preceeding 
PCI. The primary efficacy endpoint of CIRCUS is a composite of 1-year all-cause mortality, 
rehospitalization for heart failure or heart failure worsening during inital hospitalization, and left 
ventricular adverse remodelling as determined by sequential transthoracic echochardiography. 
Secondary outcomes will be tested using a hierarchical sequence of left ventricular (LV) ejection 
fraction and absolute measurements of LV volumes. The composite of death and rehospitalization 
for heart failure or heart failure worsening during inital hospitalization will be further assessed at 
three years after the initial infarction. 
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Results  
Recruitment lasted from April 2011 to February 2014. The CIRCUS trial has recruited 975 
patients with acute anterior myocardial infarction. The 12-months results are expected to be 
available in 2015. 
Conclusions  
The CIRCUS trial is testing the hypothesis that cyclosporine in addition to early revascularization 
with PPCI compared to placebo in patients with acute anterior myocardial infarction reduces the 
incidence of death, heart failure and adverse LV remodelling at one-year follow-up.  
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 4 
Background 
Studies have demonstrated that infarct size is a major determinant of prognosis after AMI 
1, 2
. 
Interventions aimed at reducing infarct size might therefore be of major clinical interest to 
improve the outcome of AMI patients. Timely reperfusion by primary percutaneous coronary 
intervention is the standard of care for AMI 
3
. The progress in the access to and efficiency of 
primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction 
(STEMI) patients during the last decade is one of the main factors underlying the improvement in 
STEMI patients clinical outcomes 
4
.  
However, experimental and clinical reports indicate that reperfusion has deleterious effects, 
including myocardial stunning, induction of ventricular arrhythmias, no reflow and lethal 
reperfusion injury 
5, 6
. Irreversible damage occurring after reperfusion may account for up to 40% 
of the final infarct size 
7
. 
Accumulating evidence suggests that cardiomyocyte mitochondria play a key role in lethal 
reperfusion injury 
8-11
. The opening of a nonspecific high conductance channel (called the 
mitochondrial permeability transition pore) in the inner mitochondrial membrane results in the 
collapse of the membrane potential, the uncoupling of the respiratory chain, the release of 
cytochrome c and other proapoptotic factors and the depletion of ATP; these metabolic 
alterations may lead to cardiomyocyte death 
12
. Calcium overload and excessive production of 
reactive oxygen species caused by sudden reperfusion of the ischemic myocardium can trigger 
the opening of the mitochondrial permeability transition pore 
9, 12-14
.  
In addition to its well-known immunosuppressive properties, cyclosporine is a potent inhibitor of 
mitochondrial permeability transition pore
15
. Several reports indicate that cyclosporine given at 
the time of reperfusion limits lethal reperfusion injury under experimental conditions 
9, 16-18
. 
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 5 
Recently, a small proof-of-concept clinical study in STEMI patients showed that cyclosporine 
given immediately prior to reperfusion could reduce infarct size as measured by CMR by 
approximately 20%
19
.  
This underlines the need for a phase III randomized trial to address the clinical efficacy of 
cyclosporine in addition to PPCI for acute myocardial infarction patients. The CIRCUS trial was 
designed to test the hypothesis that a single intravenous administration of cyclosporine 
immediately before PCI reduces the 1-year composite of mortality, rehospitalization for heart 
failure or heart failure worsening during initial hospitalization, and left ventricular remodelling in 
anterior STEMI patients referred for PPCI.  
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Study objectives 
In the CIRCUS trial, patients with anterior STEMI undergoing PPCI are randomized to a single 
intravenous bolus of 2.5 mg/kg of cyclosporine (CiclomulsionÒ, NeuroVive Pharmaceutical AB, 
Lund, Sweden) or 2.5 mg/kg of matching placebo.  
The primary objective of the study is to determine whether the administration of a single 
intravenous bolus of cyclosporine before reperfusion compared to placebo in patients with large 
amounts of myocardium at risk (anterior STEMI) results in reduced incidence of all-cause 
mortality, rehospitalization for heart failure or heart failure worsening during initial 
hospitalization and adverse left ventricular (LV) remodelling as assessed by transthoracic 
echocardiography at 1-year follow-up. Adverse LV remodelling is defined here as an increase in 
LV end-diastolic volume (LVEDV) ≥ 15% between the initial LVEDV and follow-up LVEDV at 
one-year.  
The reasons for choosing this primary objective are:  
- all-cause mortality is a hard clinical endpoint and in the first-year following anterior MI, the 
main cause of death is of cardio-vascular origin. In addition, in this off-label use of cyclosporine, 
it appeared mandatory to have all-cause death as an endpoint. This is to account for any potential 
unexpected cardiac or extra-cardiac effects of cyclosporine. 
- heart failure events are closely related to the amount of myocardial tissue damage induced by 
the ischemic and reperfusion injuries 
2
. As our primary hypothesis is that cyclosporine 
significantly reduces infarct size, we expect a significant reduction of heart failure events after 
AMI. 
- adverse LV remodelling is closely related to the final infarct size 
20
. If cyclosporine 
significantly reduces the final infarct size, it should also reduce the adverse LV remodelling 
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 7 
process. The link between the adverse remodelling process and hard clinical events is unclear. 
The long-term follow-up at 3-years of the CIRCUS study should provide evidence for this 
relationship.  
An important secondary objective is to evaluate the clinical outcome at 36 months defined by the 
composite endpoint of death and rehospitalization for heart failure or heart failure worsening 
during inital hospitalization. 
 
Study population and patient selection 
The CIRCUS study is a prospective, randomized, international, multicenter, placebo-controlled 
trial in patients with anterior acute STEMI referred for PPCI. 
The study is ongoing in 57 centers in France, Belgium and Spain. The study is being performed 
according to the principles of the Declaration of Helsinki (1964, and its text revisions), and 
approval has been obtained from ethics committees in the countries concerned. The trial has been 
registered under www.clinicaltrials.gov: NCT01502774 and EudraCT number: 2009-013713-99. 
The study population consists of 975 anterior acute STEMI patients enrolled at 52 centers in 
France, 4 centers in Belgium and 1 in Spain.  
Recruitment started April 2011 and was completed in February 2014. The final results of the one-
year clinical composite endpoint are expected end of Q2 2015.  
The main inclusion and exclusion criteria are listed in Table 1.  
Consent was obtained in an emergency setting. In all centers, patients were informed as soon as 
possible of the ongoing trial prior to coronary angiography. The angiogram was performed to 
collect TIMI flow data. If the selection criteria were completed, then the informed consent was 
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 8 
obtained. If the written informed consent could not be obtained, an oral informed consent was 
obtained and ascertained by an impartial witness, independent of study investigator, or a patient’s 
legal representative or relative. In the latter case, the study investigator obtained the patient’s 
written informed consent as soon as possible after randomization.  
Randomization and treatment protocol 
The investigation schedule is depicted in Figure 1 and the study flow chart is shown in Table 2. 
Patient randomization was performed centrally by internet after secure login into the on-line case-
report form (CRF) of the study, with a randomization ratio of 1:1 using a computer-based 
randomization program, stratified by center. 
All patients received revascularization by PPCI plus medical treatment according to guidelines 
3
. 
During PCI, the choice of stent (bare-metal or drug-eluting stent) was left to the discretion of the 
operator. The use of thrombus aspiration, intra-coronary glycoprotein IIb/IIIa inhibition and 
devices to prevent distal embolization was left to the discretion of the operator.  
After coronary angiography but before angioplasty, patients who met the enrolment criteria were 
randomly allocated to either the placebo or the cyclosporine group. Before the first balloon 
inflation, patients received an intravenous bolus injection of 2.5 mg/kg of the study drug. For 
each group, the study drug was injected slowly (over 2 to 3 minutes) via a catheter positioned 
within a peripheral vein.  
The investigational medicinal product is cyclosporine (CiclomulsionÒ, NeuroVive 
Pharmaceutical AB, Lund, Sweden) 
21
. The matching placebo of CiclomulsionÒ (NeuroVive 
Pharmaceutical AB, Lund, Sweden) is a lipid emulsion composed with refined soya-bean oil, 
medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, 
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 9 
water for injection). The qualitative composition of CiclomulsionÒ and its placebo only differed 
by the presence or absence of cyclosporine. The final emulsions were visually indistinguishable.  
All study procedures are detailed in Table 2. 12-lead electrocardiogram, coronary angiography 
and echocardiographic data procedures are presented below. 
Assessment of the clinical outcomes will be performed by 3-telephone interviews at 30-day, 3-
month and 6 month follow-up. The primary outcome will be measured during a routine 
cardiology visit performed at 1- and 3-years.  
Electrocardiogram (ECG) 
For all patients five 12-lead ECGs will be obtained at admission (before PCI), after PCI (60 to 90 
minutes after PCI), at hospital discharge, at 1 year (±8 weeks) and 3 years (±8 weeks). All ECG 
recordings will be sent to the coordination center for a centralised reading in the CIRCUS ECG-
core laboratory. Expert readers will assess the maximal ST-segment deviation in the anterior 
leads and the number of significant Q waves for each recording. 
Coronary Angiography 
For all patients, the coronary angiography performed at admission will be stored digitally and 
sent to the coordinating center for centralized reading. All angiographic data will be analyzed on 
a specific workstation (Osirix) by a single expert observer blinded to all other clinical data. Site 
of occlusion, initial and final TIMI flow, collateral circulation (Rentrop grade), stent number, 
multi-vessel disease status, coronary interventions and complications, angiographic estimate of 
the area at risk size (APPROACH score
22
) will be assessed for each patient. 
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Cardiac biomarkers 
For all patients, at least two blood samples for cardiac biomarkers (total creatine kinase (CK), 
troponin T or I) will be performed and measured locally. Biomarkers will be assessed at 
admission and at 4 hours (±30 minutes) after reperfusion.  
Transthoracic Echocardiography 
For all patients, conventional transthoracic echocardiography will be performed in all patients 
after PCI during the index hospitalization (within the first week following admission), at one year 
(±8 weeks) and 3 years (±8 weeks) after AMI. 
Patients are scanned in the left supine position from an apical window. Images are obtained using 
a 3.5 MHz transducer, at a depth of 12 to 20 cm in parasternal and apical views. Three cardiac 
cycles of the apical 4-, 3-, and 2-chamber views are captured in 2D.  
Left ventricular volumes are measured and the biplane Simpson’s rule is applied
23, 24
. LV 
remodelling will be assessed at 1 year (±8 weeks) versus baseline echocardiography (48 hours ± 
48 hours) according to the following formula: 
(LVEDV 1 year-LVEDV baseline/ LVEDV baseline) x 100. 
All echocardiographic data are stored digitally and sent to the coordinating center for a 
centralized corelab reading. Two blinded expert operators will centrally assess data on a specific 
workstation. 
Primary and secondary end points 
The primary end point is a composite of 1-year all-cause mortality, rehospitalization for heart 
failure or heart failure worsening during inital hospitalization, and left ventricular adverse 
remodelling as determined by sequential transthoracic echochardiography. 
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Key secondary endpoints include LV ejection fraction (LVEF), LV end-diastolic and end-systolic 
volumes assessed within the first week following admission and at one and three years. 
Secondary endpoints also include all individual components of the primary endpoint taken 
separately (all cause mortality; rehospitalization for heart failure or worsening of initial heart 
failure status during initial hospitalization; adverse LV remodelling).  
 
Other secondary endpoints used in several previous STEMI trials
25, 26
 are being examined across 
both arms. They include the following:  
1) Major adverse ischemic cardiac events: unstable angina or reinfarction (using the 
universal definition of myocardial infarction definition
27
) and unplanned revascularization 
by either PCI or coronary artery bypass graft; 
2) Major adverse cardiac and cerebrovascular events;  
3) Implantable cardioverter defibrillator implantation for primary or secondary prevention;  
4) NYHA (New York Heart Association) dyspnea status at one and three years; 
5) Incidence of complete ST-segment resolution 60±30 minutes after the last angiogram; 
6) 4±2-hours post-admission levels of serum troponin and creatine kinase; 
We did not have the means to assess the myocardial biomarker release kinetics after reperfusion 
conversely to our previous trial 
19
. The sample size, the change in local routine practices and the 
heterogeneity of biomarker assays (especially for hypersensitive troponins) prevented us from 
comparing the biomarker release between both groups. Post-reperfusion LV arrhythmias (non-
sustained and sustained ventricular tachycardia and ventricular fibrillation) will also be compared 
between both groups, as another exploratory endpoint.  
Besides efficacy, the trial addresses the issue of safety of a 2.5 mg/kg cyclosporine intravenous 
bolus given immediately prior to reperfusion. Safety assessment includes acute renal failure as 
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assessed by serial measurement of creatinine between baseline and 48 hours after admission and 
any other serious adverse events declared by investigational centers as being potentially related to 
investigative drug/placebo.  
Substudy 
The CIRCUS trial has one Cardiac Magnetic Resonance Imaging sub-population analysis. It 
plans to evaluate infarct size, microvascular obstruction, LV remodelling and LV systolic 
function recovery. This exploratory sub-population analysis will be performed only in centers 
fulfilling technical requirements and where CMR is available in routine practice
28, 29
. There is no 
prespecified sample size for this sub-population analysis. 
 
Study monitoring and adjudication committee 
An independent Data Safety Monitoring Board (DSMB) that includes one cardiologist, one 
pharmacologist and one bio-statistician will monitor the trial. The DSMB will receive the results 
of two blinded interim analyses performed after 300 and 500 inclusions. Interim safety analyses 
will assess the one-month all-cause mortality and acute renal failure in both study groups. The 
DSMB will be entitled to make recommendations to the steering committee regarding the 
continuation of the study. 
All clinical and safety endpoints will be adjudicated by a Clinical Endpoints Committee (CEC), 
blinded to the patients' assigned treatment, based on data provided by the investigational centers.  
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Study Funding 
The CIRCUS trial is an investigator-initiated trial that is supported by a national PHRC program 
funded by the French Ministry of Health (PHRC National 2010). Furthermore, it is supported by 
grants from NeuroVive Pharmaceutical AB, Lund, Sweden, that also provides the study treatment 
CiclomulsionÒ and matching placebo.  
 
Statistical design  
We estimated that the proportion of patients reaching the endpoints (death, hospitalization for 
heart failure (HF), LV remodelling) in the control group over the planned 12 months of the study 
would be 7% for death and 42% for heart failure and LV remodelling combined. The expected 
proportion of the combined endpoint was estimated to 49 % taking into account the overlap of 
heart failure and LV remodelling. An estimated 790 patients (395 patients per group) would be 
required for the study to have 80% power to detect a 20% reduction in the relative risk with a 
two-sided alpha level of 5%. We estimated that the assessment of LV remodelling would be 
missing for 14% patients surviving at 1 year, and the sample size was increased to adjust for 
missing values. In addition, a further 10% was added to accommodate the fact that the sample 
size was calculated assuming the use of a chi-square test while a different model will be used for 
the analysis. The final sample size was estimated to 972 patients. The sample size was calculated 
using nQuery+nTerim 2.0. 
The primary analysis will be a modified intention-to-treat (mITT) analysis including all 
randomized patients with a valid measurement for the primary endpoint. Patients will be analysed 
in the treatment group to which they were allocated by randomization. 
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For the primary endpoint, data will be analysed by comparing the proportion of the primary 
combined efficacy endpoint at 12 months in the active group vs. the placebo group by using a 
logistic mixed effect regression model that includes treatment as ﬁxed effect and center as 
random effect. 
A hierarchial approach will be used to adjust for multiple testing of the first five endpoints:  
a) Combined incidence of (death, heart failure and increase in LVEDV > 15 % at one year),  
b) Ejection fraction (EF %) at 12 months 
c) Left Ventricular End Diastolic Volume (LVEDV) at 12 months  
d) Left Ventricular End Systolic Volume (LVESV) at 12 months 
e) Time to first event (death, hospitalization for heart failure) at 36 months.  
 
The abovementioned endpoint e), time to first event (death, hospitalization for heart failure) is 
classified as an additional primary endpoint at 36 months but will follow as endpoint number 
five in the hierarchial testing.  This since the other endpoints in the hierarchy will be analysed 
and reported at 12 months. Each subsequent test will only be considered as confirmatory 
providing the previous step(s) is/are successful at the 5%-level (p<0.05). If any of the previous 
steps is not successful, the analysis of the following steps will be considered descriptive. 
Treatment difference in EF at 12 months, LVEDV at 12 months and LVESV at 12 months will be 
estimated and analysed using mixed linear models that include treatment as ﬁxed effect and 
centre as random effect. Other covariates may be added for additional analyses of the secondary 
endpoints. Where applicable, non-parametric methods may be considered as alternative approach 
for some of the endpoints. 
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For each component of the primary endpoint and for secondary clinical outcomes endpoints such 
cardiovascular mortality, myocardial infarction, unstable angina, stroke, descriptive methods 
without formal statistical testing will be used. 
The primary analysis of CIRCUS is conducted at 12 months and at 36 months a follow-up 
analysis will be performed. The purpose of the 36-month analysis is to gain additional power for 
an additional combined endpoint of hard outcomes: time to first event [all-cause mortality, 
hospitalization for heart failure] at three years post-AMI.  
An exploratory analysis is to be conducted at 36 months to evaluate the predictive value of Left 
Ventricular End Diastolic Volume at 12 months for Major Cardiac Adverse Events (MACE) 
occurring during the subsequent 2 years follow-up. This analysis will use epidemiological 
statistical methods such as ROC (Receiver Operating Characteristics) regression and Cox 
regression, possibly also including a classical Prentice analysis 
32
. 
Study organization 
The CIRCUS Steering Committee is chaired by Michel Ovize, MD, PhD of the Claude Bernard 
University of Lyon1 - Hôpital Cardiovasculaire Louis Pradel, Lyon, France. Members of the 
committees and corelabs and participating centers with all principal investigators and sub-
investigators are listed in the online Appendix A. The Steering Committee is responsible for the 
scientific content of the protocol and oversees the trial operations and will prepare the primary 
manuscript and other publications arising from the CIRCUS Trial.  
Each participating center has a senior investigator with clinical trial experience. All trial-related 
processes will follow the standard operating procedures of the CIRCUS study protocol. The 
Clinical Investigation Center (CIC) located in Lyon, France, is the coordinating center of the 
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CIRCUS study.  
Monitoring on site of all centers is performed by the Study Sponsor, the Hospices Civils de Lyon 
(Clinical Research and Innovation Direction).  
The authors are solely responsible for the design and conduct of this study, all study analyses, the 
drafting and editing of the manuscript, and its final contents.  
Discussion 
CIRCUS is the largest prospective phase III randomized trial assessing the impact of a single 
injection of cyclosporine compared to placebo just before revascularization on a composite 
endpoint of all-cause mortality, rehospitalization for heart failure, and echocardiographic LV 
remodelling at 1-year follow up in acute STEMI patients referred to PPCI. 
During the past two decades, several negative studies have contributed to the growing skepticism 
regarding the ability of any intervention to reduce infarct size in acute MI patients. From the early 
2000s on, this pessimistic view of infarct size reduction has been reconsidered. First, major 
improvements in reperfusion therapy have helped interventional cardiologists to better control the 
conditions of myocardial reperfusion in the settings of acute coronary syndromes. Second, the 
description of the phenomenon of ischemic postconditioning in the dog model in 2003 was 
confirmed in STEMI patients in 2005
33, 34
. This contributed to confirm the existence of lethal 
reperfusion injury in STEMI patients and eventually to consider its treatment 
35
.  
As a matter of fact, several small-size proof-of-concept studies have demonstrated that ischemic 
conditioning interventions, administered before, or immediately at the onset of reflow, were able 
to reduce infarct size, attenuate myocardial no-reflow and edema and improve functional 
recovery 
33, 36, 37
. Because ischemic postconditioning by coronary angioplasty is not always easy 
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to handle (thrombotic burden, complex tortuous coronary anatomy), some investigators examined 
whether pharmacological agents might mimic ischemic postconditioning.  
Piot et al. were the first to demonstrate that a single bolus intravenous administration of 
cyclosporine prior to PCI reperfusion could reduce infarct size in STEMI patients 
19, 38
. However, 
another trial failed to find benefit of cyclosporine in combination to thrombolysis 
39
. In the 
MitoCare trial, administration of TRO40303, an agent that binds the outer mitochondrial 
membrane but does not act directly on the mitochondrial permeability transition pore, failed to 
reduce infarct size in STEMI patients 
40
.  
In a follow-up study of the Piot’s trial, Mewton et al. reported that patients who received 
cyclosporine immediately prior to PCI developed less adverse LV remodelling and displayed 
improved LV function at 6 months post-infarction 
38
. In addition, recent phase II trials have 
demonstrated that other pharmacological agents, administered prior to reperfusion, may reduce 
infarct size in STEMI patients, including intra-coronary abciximab, metoporolol or the GLP-1 
analog exenatide 
26, 41, 42
.  
However, these encouraging results remain of limited clinical relevance. A pragmatic and 
sufficiently powered trial assessing a cardioprotective intervention on well-defined clinical 
endpoints is needed for the confirmation of a significant clinical benefit and future 
implementation on a routine basis. The CIRCUS trial was thus designed with the primary 
objective to examine the potential benefit of cyclosporine on outcomes after STEMI.  
Beyond the evaluation of the impact of cyclosporine on clinical endpoints, the results are also 
expected to shed further light on the role of LV remodelling as a determinant of post-AMI heart 
failure
20, 30
. At 36 months, a composite endpoint of death and rehospitalization for heart failure or 
worsening of heart failure during initial hospitalization will be analysed as a key secondary 
endpoint. The longer follow-up will yield power for this more conventional endpoint based 
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exclusively on hard outcomes. 
The study population was defined in order to maximize the ability to detect a benefit of 
cyclosporine in preventing adverse clinical outcomes related to lethal reperfusion injury. 
Cyclosporine, as well as ischemic conditioning interventions, is known to be of potentially 
greater benefit in patients with a large area at risk
16, 19, 38
. Patients included in the CIRCUS trial 
display large areas at risk (anterior STEMI), and have an increased risk of adverse LV 
remodelling and worse clinical outcomes 
2, 30
. The CIRCUS trial was designed in a pragmatic 
way, i.e. the study treatment was administered as an adjunct to standard care, easy to add to the 
routine clinical practice in the catheterization laboratory. If this trial were positive, with a 
significant effect on all three components of the primary composite endpoint, there would be a 
rationale to recommend intravenous cyclosporine administration prior to reperfusion in patients 
presenting with anterior MI and an occluded LAD artery. Provided no significant side effects 
induced by cyclosporine were shown. The extension to all-comer STEMI patients with various 
initial TIMI status and in different infarct territories at inclusion would need further trials in these 
specific clinical situations. 
 
Summary 
Proof-of-concept phase II trials have tested the use of protective strategies in AMI to reduce the 
reperfusion-induced damage to the myocardium. The CIRCUS trial has been designed to test the 
hypothesis that on a background of early revascularization with PPCI, cyclosporine in 
comparison with placebo will improve the one-year and three-year outcomes of patients with 
acute anterior myocardial infarction. 
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Figure Legends 
Figure 1: The Circus Trial Timeline. LAD: left anterior descending coronary artery; LVEDV: 
left ventricular end-diastolic volume; PCI: percutaneous coronary intervention; STEMI: ST-
elevation myocardial infarction; TTE: transthoracic echocardiography; TIMI: thrombolysis in 
myocardial infarction. 
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Table 1: Main inclusion and exclusion criteria in the CIRCUS study 
Inclusion criteria  
1) Male and female aged ≥ 18 y, without any legal protection measure 
2) Proper health insurance coverage 
3) Presentation within 12 hours of symptom onset (chest pain, chest discomfort) 
4) ST segment elevation ≥ 0.2 mV in two contiguous anterior (V1-V6) leads on regular 12-lead 
electrocardiogram 
5) Referral to cardiac catheterization laboratory for primary percutaneous coronary intervention (PPCI) or 
rescue PCI 
6) Culprit coronary artery: Left Anterior Descending (LAD) coronary artery  
7) Initial angiographic Thrombolysis in Myocardial Infarction (TIMI) flow grade≤ 1 in LAD 
8) Informed consent obtention 
Exclusion criteria 
1) Unconsciousness or confusion 
2) Cardiogenic shock  
3) Culprit coronary artery other than LAD (left circumflex or right coronary artery), and evidence of 
coronary collaterals to the myocardial risk region (Rentrop grade≥1) 
4) Initial angiographic TIMI flow grade ≥2 in LAD 
5) History of hypersensitivity to cyclosporine 
6) History of hypersensitivity to egg, peanut or Soya-bean proteins  
7) History of chronic renal insufficiency (either creatinin clearance < 30 ml/min/1.73m² or current 
medical care for severe renal insufficiency) 
8) History of liver insufficiency 
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9) Uncontrolled hypertension at the time of admission (Systolic blood pressure > 180 mmHg and/or 
diastolic blood pressure>110 mmHg) 
10) Current medication with any compound containing Hypericum perforatum (St.-John’s-worth) or 
Stiripentol or Aliskiren or Bosentan or Rosuvastatine 
11) Female patients currently pregnant or women of childbearing age without efficient contraception  
12) Any disorder associated with immunological dysfunction ≤ 6 months prior to presentation (cancer, 
lymphoma or known positive serology for HIV, or hepatitis) 
13) Participation in another clinical trial 
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Table 2 : Diagram of data acquisition  
 Hospitalization 
1 month 
(± 2 wk) 
3 months 
(± 2 wk) 
6 months 
(± 2 wk) 
1 year 
(±8 wk) 
3 years  
(±8 wk) 
  Phone-call Phone-call Phone-call 
Clinical 
visit 
Clinical 
visit 
Written informed consent X      
Coronary-angiography   X      
Study treatment administration X      
Coronary angioplasty  X      
Clinical examination X0    X X 
ECG at admission (before and after 
PCI) 
X
0    X X 
Cardiac biomarkers (total creatine 
kinase, troponin T or I) 
X
1      
Serum creatinine, Sodium, Potassium X2      
Glycemia, Total Bilirubin, Alkaline 
phosphatases, ALT, AST, γ-GT, 
white-cell count 
X
2      
Transthoracic Echocardiography X    X X 
Blood pressure X3    X X 
Heart rate X3    X X 
NT-Pro BNP or BNP X
3
    X X 
Quality of life questionnaire      X 
27
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
 
 28 
 
  
AE and SAE records during clinical 
visits 
X    X X 
SAE records during phone calls  X X X   
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